The quality of the fragment obtained by liver biopsy for staging chronic hepatitis

Journal of Gastrointestinal and Liver Diseases

Volumn 16, Issue 3, 2007, Pages 263-266

  Sporea, Ioan ^a,b   Şirli, Roxana ^a   Popescu, Alina ^a   Cornianu, Marioara ^a   Manciu, Corina ^a   Focşa, Mircea ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b NONE   (Romania)

Author keywords

Biopsy sample quality; Chronic hepatitis; Liver biopsy

Indexed keywords

ARTICLE; AUTOIMMUNE HEPATITIS; CHRONIC HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; PRIMARY BILIARY CIRRHOSIS; QUALITY CONTROL; SAMPLE; TISSUE SECTION; WILSON DISEASE;

BIOPSY, NEEDLE; DATA INTERPRETATION, STATISTICAL; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HEPATITIS, AUTOIMMUNE; HEPATITIS, CHRONIC; HEPATOLENTICULAR DEGENERATION; HUMANS; LIVER; LIVER CIRRHOSIS, BILIARY; RETROSPECTIVE STUDIES;

EID: 34948842014     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Anonymous. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board. Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47
2. Moreno-Otero R. Therapeutic modalities in hepatitis C: challenges and development. J Viral Hepat 2005; 12: 10-19
3. Molnar GB, Cocian S, Jebeleanu L, Popa S, Feder A. Evaluarea seroepidemiologicǎ a infecţiei cu virusul hepatitic C la populaţia din 10 judeţe ale României. Rev Rom Boli Infect 2005;8:3-7.
4. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47: 1-39
5. Anonymous. Management of hepatitis C. NIH Consensus Statement. Hepatology 1997; 15: 1-41
6. Conry-Cantilena C, VanRaden M, Gibble J et al. Routes of infection, viremia and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334: 1691-1696
7. Heathcote J, Main J. Treatment of hepatitis C. J Viral Hepat 2005; 12, 223-235
8. National Institute of Health Consensus Development Conference Statement: Management of Hepatitis C. Hepatology 2002; 36: S3-S20
9. Grant A, Neuberger F. Guidelines on the use of liver biopsy in clinical practice. The British Society of Gastroenterology. Gut 1999; 45 (Suppl.4): 1-11
10. Guido M, Rugge M: Liver biopsy sampling in chronic viral hepatitis. Semin Liver Dis 2004; 24: 89-97
11. Beaugrand M. [FibroScan: instructions for use]. Gastroenterol Clin Biol 2006;30:513-514
12. Sporea I, Şirli R, Cornianu M et al. How relevant is the liver biopsy with Menghini modified type needles for the diagnosis of chronic hepatitis? J Gastrointestin Liver Dis 2006; 15 (Suppl. 1): 100
13. Gebo KA, Herlong HF, Torbenson MS et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 2002; 36: S161-S172
14. Poynard T, Zoulim F, Ratziu V et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 2005; 100: 1970-1980
15. Laine F, Bendavid C, Moirand R et al. Prediction of liver fibrosis in patients with feature of metabolic syndrome regardless of alcohol consumption. Hepatology 2004; 39: 1639-1646
16. Ratziu V, le Calvez S, Imbert-Bismut F et al. Diagnostic value of biochemical markers (FibroTest) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Hepatology 2003; 38: 729A
17. Rosenberg WM, Voelker M, Thiel R et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-1713
18. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical sur-rogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003; 38: 481-492
19. Sandrin L, Fourquet B, Hasquenoph JM et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 23: 1705-1713
20. Foucher J, Vergniol J, Castera L et al. Fibrosis evaluation in chronic liver diseases: comparison of FibroScan with liver biopsy, FibroTest, Forns score, APRI, hyaluronan, prothrombin time and AST/ALT ratio. 40-th Annual Meeting of the EASL, Paris, 2004 (abstract)
21. Castera L, Vergniol J, Foucher J et al: Prospective comparison of transient elastography, Fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350
22. Colletta C, Smirne C, Fabris C et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005; 42: 838-845
23. European Association for the Study of the Liver. Consensus statement. EASL: International consensus Conference on hepatitis C. J Hepatol 1999; 26 (Suppl.): 2S-10S
24. Bacon BR. All hepatitis C patients should be offered liver biopsy and treatment. AGA Perspectives 2005; 4: 4-12